Dovilamir 50 mg, 300 mg FC tablets
PDF Leaflet Revision Date: 23 April 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults aged 18 years and older.
Dosage (summary)
One tablet orally once daily, without regard to food.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; effective contraception required for women of childbearing age.
Key Drug Interactions
- Rifampicin decreases dolutegravir levels
- Avoid with dofetilide and pilsicainide
Contraindications
- Hypersensitivity to components
- Uncontrolled renal failure
- Pregnancy
- Lactation
Common side effects
- Nausea
- Diarrhoea
- Headache
- Rash
Counselling Points
- Monitor for signs of lactic acidosis
- Regular renal function tests recommended
- Continue safe sex practices to prevent HIV transmission
Serious warnings
- Lactic acidosis and severe hepatomegaly
- Risk of opportunistic infections
- Immune Reconstitution Inflammatory Syndrome (IRIS)
Important Disclaimer
The Dovilamir 50 mg, 300 mg FC tablets professional information leaflet below is the property of Umsebe Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
